Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting-Reference-Cited by-同舟云学术

Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting

Published:2013-08 Issue:8 Volume:8 Page:997-1003
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Chouaid Christos,Agulnik Jason,Goker Erdem,Herder Gerarda J.M.,Lester Jason F.,Vansteenkiste Johann,Finnern Henrik W.,Lungershausen Juliane,Eriksson Jennifer,Kim Kun,Mitchell Paul L.R.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Impact of the new lung cancer staging system for a predominantly advanced-disease patient population;Chien;J Thorac Oncol,2010

3. Quality of life of long-term survivors of non-small-cell lung cancer;Sarna;J Clin Oncol,2002

4. Quality of life and symptom burden among long-term lung cancer survivors;Yang;J Thorac Oncol,2012

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer;Cancer Medicine;2024-08

2. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China;BMJ Open;2024-08

3. Datopotamab deruxtecan versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer: A cost-effectiveness analysis;Lung Cancer;2024-08

4. Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives;Frontiers in Pharmacology;2024-06-10

5. Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands;Value in Health;2024-06